FDA green lights Priovant drug for rare skin disease
FDA green lights Priovant drug for rare skin disease
Priovant Therapeutics
Private
Biopharmaceutical company focused on developing novel therapies for autoimmune and inflammatory diseases. Its lead asset LISRAYA (brepocitinib) received FDA approval for dermatomyositis, with Orsini Specialty Pharmacy serving as the specialty pharmacy partner.
Company Info
Upcoming Milestones & Key Dates
2026
Commercial Launch
LISRAYA commercial launch
Clinical Development Pipeline
LISRAYA (brepocitinib)
Target: TYK2/JAK1Recent News
Orsini to Serve as Specialty Pharmacy Partner for Priovant's LISRAYA™ (brepocitinib)
Orsini Specialty Pharmacy selected as the specialty pharmacy partner for Priovant Therapeutics' newly approved dermatomyositis drug LISRAYA (brepocitinib).
Priovant nabs first FDA approval for targeted tablet in dermatomyositis
Priovant nabs first FDA approval for targeted tablet in dermatomyositis
FDA Nod for Inflammation Drug Notches Wins for Rare Disease Patients, Roivant's Biz Strategy
The FDA has approved Roivant Sciences' inflammation drug brepocitinib (Lisraya) for dermatomyositis, a rare autoimmune disease. The approval validates Roivant's subsidiary-led drug development strategy.